Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al .
Jeffrey S WeberMario MandalaPaolo Antonio AsciertoJames LarkinPublished in: Journal for immunotherapy of cancer (2022)